-- Appoints Arwa Shurrab as Vice President of Regulatory Affairs and Jamie Ellen Siegel, M.D., as Head of Clinical Development --
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced two key additions to its clinical hemophilia programs with the appointments of Arwa Shurrab as vice president of regulatory affairs and Jamie Ellen Siegel, M.D., as the head of clinical development.
“The addition of Arwa Shurrab and Dr. Jamie Siegel, with their extensive regulatory and clinical hematology experience, significantly strengthens our hemophilia development team,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We are confident that their contributions will help us move forward in our clinical development program for our subcutaneous, prophylactic FVIIa, marzeptacog alfa (activated), and FIX, CB 2679d, candidates.”
Arwa Shurrab brings to Catalyst nearly 25 years of regulatory affairs experience in the hematology field. She has worked extensively leading regulatory and chemistry, manufacturing and controls (CMC) activities. Before joining Catalyst, Arwa was the director of regulatory affairs at Shire, where she served as a director leading the Hematology CMC team in the development of strategic plans and worldwide regulatory submissions. Prior to Shire, she spent over 20 years at Baxter/Baxalta leading regulatory activities for hemophilia products, including but not limited to major BLA approvals and expansion to more than 70 countries. Earlier in her career, Arwa held various positions in quality control and quality assurance. Arwa holds a bachelor of science in chemistry with a minor in biology from The American University in Cairo.
Jamie Ellen Siegel, M.D., brings to Catalyst over 30 years of clinical, clinical laboratory, and program development experience in the hematology field, particularly in hemophilia, with the last ten years in government and industry settings. Jamie was director of the Hemophilia and Thrombosis Center, Cardeza Foundation Special Hemostasis Laboratory, and associate professor of medicine at Thomas Jefferson University. She was co-director of the Medical Advisory Board for the Hemophilia Federation of America and has received numerous humanitarian awards from hemophilia patient advocacy groups. Before joining Catalyst, Jamie held a number of high-level positions, including medical director at Novo Nordisk and global clinical leader at Bayer where she worked on two major hemophilia programs, and was Chief, Thrombosis and Hemostasis branch at the National Institutes of Health. She has overseen numerous clinical trials and has authored over 35 hematology publications, including almost 20 peer-reviewed papers, seven peer-reviewed review articles, and seven book chapters. Jamie received her medical degree from the Medical College of Pennsylvania and holds a bachelor of arts from Lehigh University.
About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia.
For more information, please visit www.catbio.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements included in this press release regarding our strategy, the potential uses and benefits of CB 2679d and marzeptacog alfa (activated) and development plans for these product candidates are forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Catalyst makes, including, but not limited to, the risk that clinical trials and studies may be delayed and may not have satisfactory outcomes, that potential adverse effects may arise from the testing or use of Catalyst’s products, the risk that costs required to develop or manufacture Catalyst’s products will be higher than anticipated, competition and other factors that affect our ability to successfully develop and commercialize our product candidates, and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. Catalyst does not assume any obligation to update any forward-looking statements, except as required by law.
Fletcher Payne, CF
Catalyst Biosciences, Inc.
Josephine Belluardo, Ph.D.
LifeSci Public Relations
Catalyst Biosciences, Inc.